Efficacy
DISEASE PROGRESSION
By the data cutoff date, 66 (66.0%) of 100 patients had disease progression or died. The median PFS was 11.8 months (95% CI, 8.4–15.1; Fig. Kaplan–Meier curves for progression-free survival. Further analyses showed that the median PFS was 8.2 months (95% CI, 3.0–20.7) in subgroup A (progression during adjuvant trastuzumab; Seven of 100 patients achieved confirmed CR and 63 achieved confirmed PR, with a confirmed ORR of 70.0% (95% CI, 60.0–78.8). Median duration of response was 13.8 months (95% CI, 10.2–19.3). Seven patients with CR were all from subgroup B. The ORR was significantly higher in subgroup B than in subgroups A and C (Additional file Waterfall plot for best percent change in target lesions from baseline among individual patients (